Verily & Samsung Partner to Integrate Galaxy Watch 8 into Precision Health Platform at HIMSS26

The Galaxy Watch 8 includes several health monitoring capabilities that have received US Food and Drug Administration clearance.

At HIMSS26, Verily Life Sciences and Samsung Electronics America announced a partnership to integrate the Samsung Galaxy Watch 8 into Verily’s precision health platform, Pre, enabling life sciences organizations and government researchers to conduct real-world studies using continuous wearable data.

The collaboration focuses on combining consumer wearable technology with clinical research infrastructure. Through the integration, sensor data collected from the Galaxy Watch 8 will feed directly into Verily’s research platform, supporting remote monitoring and longitudinal data collection for clinical studies.

The Galaxy Watch 8 includes several health monitoring capabilities that have received US Food and Drug Administration clearance. These include assessments for moderate-to-severe obstructive sleep apnea and notifications for irregular heart rhythms such as atrial fibrillation. The device also provides continuous monitoring of blood oxygen saturation (SpO2) and body composition metrics.

Under the partnership, data captured by the smartwatch will be ingested into Verily’s Viewpoint Evidence platform. Research sponsors will then be able to use Verily’s Refinery tool to harmonize the incoming data streams and its Workbench environment to conduct artificial intelligence and machine learning-based analysis and modeling.

According to the companies, the combined solution is designed to simplify the use of consumer wearable data in clinical research. Historically, one of the main challenges in using wearable devices for trials has been integrating large volumes of sensor data with other clinical information sources.

“The use of consumer-friendly devices in clinical research makes it easier for participants to engage in studies, while enabling sponsors to use advanced biomarkers to generate high-quality data,” said Scott Burke, Chief Technology Officer at Verily.

The partnership also provides research sponsors with access to longitudinal datasets built from consented participants. These datasets combine Samsung sensor data with electronic health records, patient surveys, and other third-party information sources at the individual level.

By harmonizing wearable data with traditional clinical datasets, the platform aims to support large-scale observational studies and decentralized trials where continuous health monitoring can provide additional clinical insights.

Stay tuned for more such updates on Digital Health News